Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
申请人:Bristol-Myers Squibb Company
公开号:US09308236B2
公开(公告)日:2016-04-12
The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
Further reactions of t-butyl 3-oxobutanthioate and t-butyl 4-diethyl-phosphono-3-oxobutanthioate : Carbonyl coupling reactions, amination, use in the preparation of 3-acyltetramic acids and application to the total synthesis of fuligorubin A.
作者:Steven V. Ley、Stephen C. Smith、Peter R. Woodward
DOI:10.1016/s0040-4020(01)88210-7
日期:1992.1
for the preparation of homologated derivatives suitable for amination in the presence of silver (I) trifluoroacetate to afford the corresponding β-ketoamides is discussed. In particular Wadsworth-Emmons coupling reactions of (2) with various carbonyl compounds gave good yields of E-substituted products. Many of the β-ketoamides were shown to be suitable precursors for 3-acyltetramic acids using a Dieckmann
MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS
申请人:Bristol-Myers Squibb Company
公开号:US20140294898A1
公开(公告)日:2014-10-02
The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
Macrocyclic Inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 Protein/Protein Interactions
申请人:BRISTOL-MYERS SQUIBB COMPANY
公开号:US20160340391A1
公开(公告)日:2016-11-24
The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.